Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

48.12 +0.84 (+1.79%)
Streaming Delayed Price Updated: 11:21 AM EST, Dec 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
42 43 Next >
Nicotine Surges as Smoking Sags
NetworkNewsWire Editorial Coverage New York, NY – May 24, 2022 – Seems like yesterday people were smoking cigarettes everywhere; many people still have memories of Grandpa puffing on his Camels. It... 
Via FinancialNewsMedia
News headline image
GSK Turnaround Story ↗
GSK is already gearing up for what it hopes will be a bright future. On April 13, GlaxoSmithKline announced a $1.9 billion deal to purchase a U.S. biotech company, Sierra Oncology. 
Via Talk Markets
News headline image
GlaxoSmithKline: Dividend Insights ↗
Wednesday marks the last chance for investors to receive the next dividend payout from GlaxoSmithKline (NYSE:GSK). 
Via Benzinga
News headline image
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield ↗
Now that all major biopharmaceutical earnings are in, we can review the financial metrics and see if our portfolio needs re-balancing. 
Via Talk Markets
News headline image
HC Wainwright Says This Stock Is Well Capitalized For Value Realization Of Pipeline, Despite COVID-19 Uncertainty ↗
 
Via Benzinga
News headline image
Recap: GlaxoSmithKline Q1 Earnings ↗
GlaxoSmithKline (NYSE:GSK) reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Germany Inks COVID-19 Vaccine Deal With CureVac, GSK Until 2029 ↗
 
Via Benzinga
Watch for Continued Gains in Shares of GlaxoSmithKline PLC (GSK)
Via Investor Brand Network
News headline image
Why Roche's Flop In Lung Cancer Hammered Arcus, Iteos And Others ↗
Roche isn't the only company working on an anti-TIGIT molecule. 
Via Investor's Business Daily
News headline image
Dividend Income Update April 2022 ↗
With May already underway it is time for all dividend income investors to look back at the previous month and see how much passive dividend income their portfolios generated. 
Via Talk Markets
News headline image
GlaxoSmithKline Clocks 32% Topline Growth Buoyed By COVID-19 Therapy, Shingrix Vaccine ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Watch for Continued Gains in Shares of GlaxoSmithKline PLC (GSK)
Via Investor Brand Network
News headline image
Why Did FDA Pull Authorization For GSK-Vir's COVID-19 Therapy? Read Here ↗
 
Via Benzinga
News headline image
GlaxoSmithKline's Earnings Outlook ↗
GlaxoSmithKline (NYSE:GSK) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
Public-health Authorities in US, UK, Probe Mysterious Cases Of Severe Hepatitis In Young Kids: WSJ ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Quest Diagnostics' COVID-19 Testing Sales Decline 28% In Q1; Lifts FY22 EPS Guidance ↗
 
Via Benzinga
News headline image
4 Undervalued Biotech Stocks to Add to Your Buy List ↗
These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns. 
Via InvestorPlace
News headline image
As Evolving Pandemic Response, Officials Shift To Personal Choice On COVID-19 Boosters, Masks: WSJ ↗
In the latest phase of the COVID-19 pandemic, federal and local officials are leaving it up to people to assess if they need booster shots, whether to wear a mask and how long to isolate after a... 
Via Benzinga
News headline image
The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More ↗
Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting... 
Via Benzinga
News headline image
Why Is Sierra Oncology (SRRA) Stock Up Today? ↗
Late-phase cancer treatment company Sierra Oncology is up big today after being acquired by GlaxoSmithKline. SRRA stock is soaring. 
Via InvestorPlace
News headline image
Sierra Oncology Stock Is Soaring: Here's Why ↗
Sierra Oncology Inc (NASDAQ: SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE: GSK) for $55 per share in... 
Via Benzinga
News headline image
Biotech Stock Sierra Soars On GSK Buyout As Halozyme Nabs Antares ↗
GlaxoSmithKline said Wednesday it will buy Sierra Oncology for $1.9 billion, sending the biotech stock flying. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal 
Via Benzinga
News headline image
GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
Rise and shine, trader! Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
News headline image
Watch For Continued Gains In Shares Of GlaxoSmithKline PLC (GSK) ↗
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
News headline image
Highly Rated GlaxoSmithKline Eyes Breakout After Racking Up Series Of Wins ↗
The move comes after the FDA shut down its Vir-partnered Covid antibody, however. 
Via Investor's Business Daily
News headline image
What Is RSV, And Why Is Pfizer Paying Up To $525M For Treatment Candidates? ↗
Pharma giant Pfizer, Inc. (NYSE: PFE), which has found huge success with its COVID franchise, is now looking to conquer another frontier. 
Via Benzinga
< Previous 1 2
...
27 28 29 30 31 32 33 34 35
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.